Orbital marginal zone B-cell lymphoma of Malt: Radiotherapy results and clinical behavior

Journal Article · Mon May 01 04:00:00 EDT 2006 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2005.1· OSTI ID:20793479

Suh, Chang-Ok ^[1]; Shim, Su Jung ^[1]; Lee, Sang-wook ^[1]; Yang, Woo Ick ^[2]; Lee, Sang Yeul ^[3]; Hahn, Jee Sook ^[4]

---

1. Department of Radiation Oncology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul (Korea, Republic of)
2. Department of Pathology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul (Korea, Republic of)
3. Department of Ophthalmology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul (Korea, Republic of)
4. Department of Hemato-oncology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul (Korea, Republic of)

Purpose: To elucidate the clinical behavior and treatment outcome of low-grade primary orbital lymphoma arising from mucosa-associated lymphoid tissue (Malt). Methods and Materials: Forty-eight patients with pathologically confirmed marginal zone B-cell lymphoma of MALT were treated with radiotherapy (RT). Thirty-eight patients (79.1%) received thorough staging workup studies including bone marrow biopsy. Radiation doses ranged from 5.4 to 30.6 Gy (median, 30.6 Gy). Median follow-up period was 70 months. Results: Only 2 patients revealed extraorbital lymphoma involvement (bone marrow, skin). Forty-six of 52 eye lesions showed complete response to RT. Six lesions demonstrated a partial response and showed gradual regression during the follow-up period of 39-72 months. Three patients experienced local recurrences at 34, 48, and 52 months after RT, which seemed to be related to improper use of the lens shield. Salvage re-RT was successful. The 10-year actuarial relapse-free survival, cause-specific survival, and overall survival rates were 93.1%, 97.9%, and 86.9%, respectively. Conclusion: Most of the MALT lymphoma of the orbit was localized at diagnosis and extraorbital relapse rarely occurred. Therefore, extensive staging workup at the time of diagnosis and follow-up studies to detect distant relapse may not be obligatory. Low-dose RT alone with proper lens shielding is the optimum treatment modality for orbital MALT lymphoma.

• OSTI ID: 20793479
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 1 Vol. 65; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BIOPSY
BONE MARROW
DIAGNOSIS
LYMPHOMAS
MUCOUS MEMBRANES
PATIENTS
RADIATION DOSES
RADIOTHERAPY
SHIELDING
SHIELDS
SKIN